Hans van Eenennaam, one of the scientists who discovered the pembrolizumab checkpoint antibody, has been promoted to the role of executive vice president for antibody research and site head of Aduro Biotech Europe, part of Aduro Biotech Inc. Dr van Eenennaam was previously chief operating officer of BioNovion, a company that he co-founded in 2011. Prior to that, he held positions at NV Organon, which was acquired by Schering-Plough Corp in 2007 and later by Merck & Co.
Aduro announced the appointment on 6 March 2018.
Copyright 2018 Evernow Publishing Ltd.